Nephrology

Dual eligibility was a proxy for high social risk in a retrospective study that compared outcomes in that group with individuals with other types of health insurance coverage.

Researchers found that nearly 28% of hospitalized chronic liver disease patients with acute kidney injury had alcohol-related disorders, as did almost 60% with hepatorenal syndrome.

Sibeprenlimab would be offered in a prefilled syringe for subcutaneous injection. The PDUFA target action date is Nov. 28, 2025.

Men and people ages 45 and older face additional risk of serious kidney conditions six to 12 months after their viral illness, a study finds.

The research is noteworthy given a Supreme Court decision that could result in many dialysis patients switching from commercial insurance plans to Medicare.

Having a child recipient and helping someone in need – especially if they knew them – were among the top reasons that people would consider living kidney donation, a new study found.

University of Pittsburgh Medical School researchers walk us through multiple approaches they’ve tried in the past, are currently using or plan to use in the future, as well as the significant challenges ahead.

Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost of $162,500 annually.

Previous research has found that immigrants have lower rates of heart disease, diabetes, dementia and other chronic health conditions compared with nonimmigrants. A new study adds kidney disease to the list.

This is the third approval for Fabhalta (iptacopan), which was discovered and developed by Novartis.

The Acute Dialysis and Pheresis Therapies (ADAPT) Program has grown from nine nurses to 12.

Patients with acute kidney injury requiring temporary hemodialysis often follow the protocol used for people on long-term dialysis, despite significant pathophysiological differences between the two.

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common complication of type 2 diabetes.

A Q&A with Jonathan Barratt, Ph.D., FRCP.

Vafseo, an oral therapy to treat patients with anemia due to chronic kidney, will be available in January 2025. About 40% of patients who could be treated with Vafseo have coverage through Medicare Advantage plans.

How successful accountable care organizations (ACOs) have been in bringing about value-based care hinges, of course, on how success is defined. CMS’ comprehensive end-stage renal disease (ESRD) care model is a good example.